Pipeline
Explore Hoba Therapeutics’ R&D projects: HB-086 for neuropathic pain and HB-097 for hearing loss, both in preclinical development.
![Science,Laboratory,Test,Tubes,,,Laboratory,Equipment](https://hobatherapeutics.com/wp-content/uploads/2024/02/shutterstock_361629392-scaled.jpg)
Our Pipeline
Program | Target indication | Discovery | Preclinical | CGMP & Regulatory Toxicology | Phase IA | Phase IB |
---|---|---|---|---|---|---|
HB-086 (Meteorin) | Neuropathic Pain | |||||
Chemotherapy-induced peripheral neuropathy |
|
|||||
Trigeminal neuralgia (orphan) |
|
|||||
Other chronic pain indications |
|
|||||
HB-097 | Sensorineural Hearing Loss | |||||
Ototoxic hearing loss |
|
|||||
Other hearing loss indications |
|
- Current status
- Planned
- Activity covered by other indication
OUR PLATFORM
Our focus at Hoba Therapeutics is the development of novel therapeutics for the treatment of neuropathic pain and hearing disorders.
Hoba Therapeutics holds the rights to two novel biopharmaceutical drugs – HB-086 and HB-097, currently in development for the treatment of chronic pain disorders and hearing loss, respectively.
HB-086 and HB-097 are therapeutic proteins and the only members of a family of recently discovered neurotrophic factors. Our research indicates that these compounds have unique actions on sensory nerve cell and their surrounding support cells.
HB-086
HB-086 is a recombinant human meteorin shown in multiple models of chronic neuropathic pain to provide robust and long-lasting relief through a novel mechanism of action. Meteorin is known to have several functions, including inducting and directing neurite outgrowth, neuroprotection, and myelination.
HB-086 is a non-opioid treatment targeting the peripheral nervous system.
HB-086 is in late preclinical development.
HB-097
HB-097 is a recombinant human cometin. HB-097 has shown protective properties when applied to the inner ear in models of hearing loss.
HB-097 is in preclinical development.